Nkarta, Inc.
NKTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 18, 2026 | Evercore ISI | $9.00(+236%) | $2.68 | TheFly | |
| Mar 26, 2024 | Canaccord Genuity | Bill Maughan | $16.00(+67%) | $9.61 | StreetInsider |
| Mar 22, 2024 | Needham | Gil Blum | $15.00(+16%) | $12.98 | Benzinga |
| Mar 22, 2024 | Mizuho Securities | Salim Syed | $25.00(+180%) | $8.92 | StreetInsider |
| Mar 22, 2024 | Raymond James | Laura Prendergast | $16.00(+79%) | $8.92 | StreetInsider |
| Apr 26, 2022 | Raymond James | $32.00(+71%) | $18.72 | Benzinga | |
| Apr 26, 2022 | H.C. Wainwright | $36.00(+92%) | $18.72 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Stifel | maintain | Buy | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2026 |
| Needham | maintain | Buy | May 13, 2026 |
| Mizuho | maintain | Outperform | Mar 31, 2026 |
| Needham | maintain | Buy | Mar 26, 2026 |
| Stifel | maintain | Buy | Nov 11, 2025 |
| Stifel | maintain | Buy | Aug 14, 2025 |
| Needham | maintain | Buy | Aug 13, 2025 |
| Mizuho | maintain | Outperform | Jun 10, 2025 |
| William Blair | downgrade | Outperform →Market Perform | May 15, 2025 |
| Needham | maintain | Buy | May 15, 2025 |
| Needham | maintain | Buy | Apr 9, 2025 |
| Stifel | maintain | Buy | Mar 27, 2025 |
| Needham | maintain | Buy | Mar 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2025 |
| Mizuho | maintain | Outperform | Nov 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| Needham | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| Raymond James | upgrade | Outperform →Strong Buy | Aug 14, 2024 |
| Needham | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 24, 2024 |
| Needham | maintain | Buy | Jun 28, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 27, 2024 |
| Needham | maintain | Buy | May 13, 2024 |
Earnings History
Next report: Mar 24, 2027 · EPS est. $-0.42| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.54 | $-0.36 | — | — |
| May 12, 2026 | $-0.37 | $-0.39 | — | — |
| Mar 25, 2026 | $-0.37 | $-0.32 | — | — |
| Nov 10, 2025 | $-0.29 | $-0.32 | — | — |
| Aug 12, 2025 | $-0.31 | $-0.37 | — | — |
| May 14, 2025 | $-0.43 | $-0.44 | — | — |
| Mar 26, 2025 | $-0.35 | $-0.41 | — | — |
| Nov 7, 2024 | $-0.39 | $-0.37 | — | — |
News
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in O…
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026.
Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogeneic, off-the-shelf CD19-targeted CAR natural killer, or CAR NK, cell therapy for autoimmune diseases. President Nadir
Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The stock traded as low as $2.73 and last traded at $2.75. 681,083 shares were traded during trading, an increase of 13% from the average daily volume of 600,515 shares. The stock had previously closed at $2.85. Wall Street Analyst
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.
BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,300,212 shares of the company's stock, valued at approximately $17,830,000. BlackRock Inc. owned 8.81% of Nkarta as of its most recent filing